Five‐year follow‐up after percutaneous pulmonary valve implantation using the Venus P‐valve system for patients with pulmonary regurgitation and an enlarged native right ventricular outflow tract
Authors:
- 6 December 2023
- journal article
- research article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 103 (2) , 359-366
Abstract
Background: Percutaneous pulmonary valve implantation (PPVI) with the self‐expandable Venus P‐valve system is a promising treatment for patients with pulmonary regurgitation (PR) and a native right ventricular outflow tract (RVOT). However, limited data is available regarding its midterm outcomes. This study assessed the midterm clinical and echocardiographic outcomes following Venus P‐valve implantation.Methods: From 2013 to 2018, 55 patients with moderate or severe PR after surgical RVOT repair with a transannular or RVOT patch were consecutively enrolled from six hospitals in China. Five‐year clinical and echocardiographic outcomes were collected and evaluated. The primary endpoint was a freedom from all‐cause mortality and reintervention.Results: At 5 years, the primary endpoint was met for 96% of patients, corresponding to a freedom from all‐cause mortality of 96% (95% confidence interval [CI]: 86%−99%) and freedom from reintervention of 98% (95% CI: 87%−100%). Endocarditis was reported in five patients (four patients within 1 year and one patient at 5 years) following PPVI. Transpulmonary gradient and stent orifice diameter remained stable compared to at discharge (p>0.05). No paravalvular leak was reported while only 1 patient gradually increased to moderate PR during follow‐up. Significant improvement of RV diameter and LVEF (p<0.001) sustained over the 5‐year follow‐up, in consistent with remarked improved New York Heart Association(NYHA) functional class (p<0.001).Conclusion: The 5‐year results of the China VenusP Study demonstrated the midterm benefits of Venus P‐valve implantation in the management of patients with severe PR with an enlarged native RVOT by providing sustained symptomatic and hemodynamic improvement.Keywords
This publication has 17 references indexed in Scilit:
- 2020 ESC Guidelines for the management of adult congenital heart diseaseEuropean Heart Journal, 2020
- Early clinical experience with the straight design of Venus P‐valve™ in dysfunctional right ventricular outflow tractsCatheterization and Cardiovascular Interventions, 2020
- Medium-term results of percutaneous pulmonary valve implantation using the Venus P-valve: international experienceEuroIntervention, 2019
- A self-expanding percutaneous valve for patients with pulmonary regurgitation and an enlarged native right ventricular outflow tract: one-year resultsEuroIntervention, 2019
- Initial results from the off‐label use of the SAPIEN S3 valve for percutaneous transcatheter pulmonary valve replacement: A multi‐institutional experienceCatheterization and Cardiovascular Interventions, 2018
- Up to 11 years of experience with the Melody valved stent in the right ventricular outflow tractEuroIntervention, 2018
- Safety and Feasibility of Melody Transcatheter Pulmonary Valve Replacement in the Native Right Ventricular Outflow TractJACC: Cardiovascular Interventions, 2018
- Transcatheter Pulmonary Valve Implantation: A Comprehensive Systematic Review and Meta‐Analyses of Observational StudiesJournal of the American Heart Association, 2017
- Percutaneous pulmonary valve implantation with the Venus P-valve: clinical experience and early resultsCardiology in the Young, 2015
- Early clinical experience with a novel self‐expanding percutaneous stent‐valve in the native right ventricular outflow tractCatheterization and Cardiovascular Interventions, 2014